Current treatment of sepsis in children

1. DuPont, H. L., Spink, W. W. Infections due to Gram-negative organisms: An analysis of 860 patients with bacteriemia at University of Minnesota Medical Center, 1958-1966. Medicine, 1968, 48, p. 307–332.

2. Watson, R. S., Carcilo, J. A., Linde-Zwirble, W. T. et al. The epidemiology of severe sepsis in children in the United States. Am. J. Respir. Crit. Care Med., 2003, 167, p. 695–701.

3. Bone, R. C., Sprung, C. L., Sibbad, W. J. Definitions for sepsis and organ failure. Crit. Care Med., 1992, 20, p. 724–772.

4. Levy, M. M., Fink, M. P., Marshall, J. C. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS. International Sepsis Definitions Conference. Intensive Care Med., 2003, 29, p. 530–538.

5. Goldstein, B.,Giroir, B. et al. 2005. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med., 2005, 6, p. 1–8.

6. Parker, M. M., Shellhamer, J. H., Natanson, C., Alin, D. W. et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit. Care Med., 1987, 15, p. 923–929.

7. Pollack, M. M., Shellhamer, J. H., Natanson, C. et al. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med., 1984,100, p. 483–490.

8. Parker, M. M., Ognibene, F. P., Parillo, J. E. Peak systolic pressure/end-systolic volume ratio, a load independent measure of ventricular function, is reversibly decrease in human septic shock. Crit. Care Med., 1994, 22, p. 1955–1959.

9. Feltes, T. F., Pignateli, R., Kleinert, S., Mariscalco, M. M. Quantitated left ventricular systolic mechanics in children with septic shock utilizing noninvasive wall-stress analysis. Crit. Care Med., 1994, 22, p. 1647–1658.

10. Ceneviva, G., Paschall, J. A. Hemodynamic support in fluid--refractory pediatric septic shock. Pediatrics, 1998, 102, p. 19.

11. Rivers, E., Nguyen, B., Havstad, S. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med., 2001,345, p. 1368–1377.

12. Parker, M. M., Hezelzet, J. A., Carcilo, J. A. Pediatric consideration. Crit. Care Med., 2004, 32, 11 (Suppl.), p. 591–594.

13. Carcillo, J. A., Davis, A. L., Zaritsky, A. The role of early fluid resuscitation in pediatric septic shock. JAMA, 1991, 266, p. 1242–1245.

14. Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J., Norton, R. SAFE Study Investigators: A comparison of albumin of albumin and saline for fluid resuscitation in the intensive care unit. N. Engl. J. Med., 2004, 350, p. 2247–2256.

15. Nhan, N. T., Phuong, C. X. T., Kneen, R. et al. Acute management of dengue shock syndrome: A randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin. Infect. Dis., 2001, 32, p. 204–212.

16. Pollard, A. J., Britto, J., Nadel, S. et al. Emergency management of menigococcal disease. Arch. Dis. Child., 1999, 80, p. 290–296.

17. Padbury, J. F., Agata, Y., Baylen, B. G. et al. Pharmacocinetics of dopamine in critically ill newborn infants. J. Pediatr., 1990, 117, p. 472–476.

18. Allen, E., Pettigrew, A., Frank, D. Alterations in dopamine clearence and catechol-O-metyltransferase activity by dopamine infusions in children. Crit. Care Med., 1997, 25, p. 181–189.

19. Bailey, A. R., Burchet, K. R. Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Br. J. Anaesth., 1997, 78, p. 97–99.

20. Marik, F. E., Mohedin, J. The contrasting effects of dopamine and norepinephrin on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA, 1994, 272, p. 1354–1357.

21. Bellomo, R., Kellum, J. A., Wisniewski, S. R., Pinsky, M. R. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am. J. Respir. Crit. Care Med., 1999, 159, p. 1186–1192.

22. Martin, C., Papazian, L., Perrin, G. et al. Norepinephrin or dopamin for the treatment of hyperdynamic septic shock? Chest, 2003, 103, p. 1826–1831.

23. McMillan, M., Chernow, B., Roth, L. Hepatic alpha I-adrenergic receptor alteration in rat model of chronic sepsis. Circ. Shock, 1986, 19, p. 426–429.

24. Melendez, E., Bachur, R. Advances in the emergency management of pediatric sepsis. Curr. Opin. Pediatr., 2006, 18, p. 245–253.

25. Morelli, A., Rocco, M., Conti, G., Orecchoni, A. et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med., 2004, 30, p. 597–604.

26. Landry, D. W., Levin, H. R., Gallant, E. M. et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 1997, 95, p. 1122–1125.

27. Matok, I., Vard, A., Efrati, O., Rubinshtein, M. et al. Terlipressin as rescue therapy for intracatable hypotension due to septic shock in children. Shock, 2005, 23, 4, p. 305–310.

28. Papoff, P., Mancuso, M., Barbara, C. S. et al. The role of terlipressin in paediatric septic shock: a review of the literature and personal experience. Int. J. Immunopathol. Pharmacol., 2007, 20, 2, p. 213–221.

29. Liet, J. M., Jacquelin, C., Orsoneau, J. L., Gras-Lequen, C., Potel, G., Rozé, J. C. The effects of milrinone on hemodynamics in experimental septic shock model. Pediatr. Crit. Care Med., 2005, 6, p. 195–199.

30. Barton, P., Garcia, J., Kouatli, A., Kitchen, L., Zorka, A., Lindsay et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double blinded, randomized, placebo-controlled, interventional study. Chest, 1996, 109, p. 1302–1312.

31. Morelli, A., Teboul, J. L. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med., 2006, 32, 5, p. 791–792.

32. Turanlahti, M., Boldt, T., Palkama, T., Antila, S. et al. Pharmacocinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatric Crit. Care Med., 2004, 5, 5, p. 457–462.

33. Egan, J. R., Clarke, A. L., Wiliams, S. et al. Levosimendan for low cardiac output: a pediatric experience. J. Intensive Care Med., 2006, 21, 3, p. 183–187.

34. Carcilo, J. A. What’s new in pediatric intensive care. Crit. Care Med., 2006, 34, 9 (suppl.), p. 183–190.

35. Van den Berghe, Wouters, G., Weekers, P. et al. Intensive insulin therapy in the critical ill patient. N. Engl. J. Med., 2001, 345, p. 1359–1367.

36. Min, M. U. T., Aye, M. et al. Hydrocortisone in the management of dengue shock syndrome. Southest Asian J. Trop. Med. Public Health, 1975, 6, p. 573–579.

37. Sumarmo, Talogo, W., Asrin, A. et al. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics, 1982, 69, p. 45–49.

38. Parker, M. M., Hazelzet, J. A., Carcillo, J. A. Pediatric consideration. Crit. Care Med., 2004, 32, 11 (Suppl.), p. 591–594.

39. Sokol, J., Jacobs, S. E., Bohn, D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth. Anal., 2003, 97, 4, p. 989–998.

40. Kinsella, J. P., Abman, S. H. Inhaled nitric oxide therapy in children. Paediatric Respiratory Reviews, 2005, 6, p. 190–198.

41. Anzueto, A., Baughman, R. P., Kalpalatha, K. G. et al. Aerosolized surfactant in adult with sepsis-induced acute respiratory distress syndrome. N. Engl. J. Med., 1996, 334, p. 1417–1421.

42. Gregory, T. J., Steinberg, K. P., Spragg et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 1997, 155, p. 1309–1315.

43. Spragg, R. G., Lewis, J. F., Wimarath, H. D. et al. Effect of recombinant surfactant protein C – based surfactant on the acute respiratory respiratory distress syndrome. N. Eng. J. Med., 2004, 351, p. 884–892.

44. Wilson, D. F., Thomas, N. J., Bauman, L. Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury. JAMA, 2005, 293, p. 470– 476.

45. Vincent, J. L., Baron, J. F., Reinhart, K. et al. Anemia and blood transfusion in critically ill patients. JAMA, 2002, 288, p. 1499–1507.

46. Samransamruajkit, R., Heranrat, T., Praphal, N. et al. Levels of protein C activity and clinical factors in early phase of paediatric septic shock may be associated with the risk of death. Shock, 2007, 21, p. 518–523.

47. Dhainaut, J. F., Laterre, P. F., LaRosa et al. Drotrecogin alfa (acivated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med., 2003, 37, p. 187–195.

48. Goldstein, B., Nadel, S., Peters, M., Barton, R. et al. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr. Crit. Care Med., 2006, 7, 3, p. 277–278.

49. Rivard, G. E., David, M., Farell, C., Schvarz, H. P. Treatment of purpura fulminans in meningococcemia with protein C concetrate. J. Pediatr., 1995, 126, p. 646–652.

50. de Kleijn, E. D., de Groot, R., Hack, C. E. et al. Activation of protein C concetrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded placebo controlled, dose finding study. Crit. Care Med., 2004, 32, 2, p. 618.

51. Bilgin, K., Yaramis, A., Haspolat et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics, 2001, 107, p. 36–41.

52. Plötz, F. B., Hulst, H. E., Twisk, J. W. R. et al. Effect of acute renal failure on outcome in children with severe septic shock. Pediat. Nefrol., 2005, 20, p. 1177–1181.

53. Kendirli, T., Ekim, M., Özcakar, Z. B. et al. Renal replacement therapy in pediatric intensive care patients: experiences of one center in Turkey. Pediatrics International, 2007, 49, p. 345–348.

54. Carcillo, J. A., Fields, A. I. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit. Care Med., 2002, 30, p. 1365–1378.